Domov › Nemalicelični pljučni rak › Kentucky › Louisville
Klinične študije za Nemalicelični pljučni rak v Louisville, KY
22 študij za Nemalicelični pljučni rak išče udeležence na lokacijah v Louisville in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.
Uradno besedilo študije (angleško)
Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Vključevanje udeležencevFaza 3
- Baptist Health Louisville, Louisville
- Baptist Health Floyd, New Albany · 4 mi stran
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
Vključevanje udeležencevFaza 1/2
- James Graham Brown Cancer Center (Melanoma/NSCLC), Louisville
A Study of ZW251 in Participants With Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- Norton Cancer Institute, Louisville
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Vključevanje udeležencevFaza 3
- Norton Cancer Institute Downtown, Louisville
- Norton Cancer Institute, Downtown, Louisville
- Norton Hospital, Louisville
- in še 4
Pan-tumor MRD Study
Vključevanje udeležencevOpazovalna študija
- Baptist Health Louisville, Louisville
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Vključevanje udeležencevFaza 3
- The University of Louisville, James Graham Brown Cancer Center, Louisville
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Vključevanje udeležencevFaza 1
- Norton Cancer Institute, Louisville
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Vključevanje udeležencevFaza 3
- Research Site, Louisville
- Research Site, Louisville
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Vključevanje udeležencevFaza 2/3
- University of Louisville, Louisville
- Local Institution - 007-388-A, Louisville
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Vključevanje udeležencevFaza 1/2
- Norton Cancer Institute Research, Louisville
Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
Vključevanje udeležencevFaza 1/2
- Norton Cancer Institute PARENT, Louisville
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Vključevanje udeležencevFaza 3
- Research Site, Louisville
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Vključevanje udeležencevFaza 1/2
- Norton Cancer Institute, Louisville
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
Vključevanje udeležencevFaza 1
- Norton Cancer Institute, Louisville
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Vključevanje udeležencevFaza 2
- University of Louisville, Louisville
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Vključevanje udeležencevFaza 1
- Norton Cancer Institute /ID# 248903, Louisville
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Vključevanje udeležencevFaza 1/2
- University of Louisville, Louisville
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Vključevanje udeležencevFaza 3
- Research Site, Louisville
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Vključevanje udeležencevFaza 2
- University Medical Center, lnc.:DBA University of Louisville Hospital, Louisville
- University of Louisville, Louisville
- UofL Health Brown Cancer Center, Louisville
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Vključevanje udeležencevFaza 1/2
- Research Site 115, Louisville
A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer
Vključevanje udeležencevFaza 1
- Research Site, Louisville
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
Vključevanje udeležencev
- James Graham Brown Cancer Center, Louisville
Študije za Nemalicelični pljučni rak v drugih mestih
- Houston, TX145 študij
- New York City, NY121 študij
- Arlington, VA104 študij
- Nashville, TN97 študij
- Boston, MA90 študij
- Los Angeles, CA87 študij
- St. Louis, MO73 študij
- Chicago, IL61 študij
- Baltimore, MD60 študij
- San Antonio, TX59 študij
- Columbus, OH57 študij
- Washington, DC55 študij
Druge študije v Louisville
- Debelost17 študij
- Prekomerna telesna teža15 študij
- Rak (vse vrste)14 študij
- Srčno popuščanje13 študij
- Akutna mieločna levkemija12 študij
- Rak jajčnikov12 študij
- Množni mielom12 študij
- Ploščatocelični karcinom glave in vratu11 študij
- Rak pljuč11 študij
- Rak dojke11 študij
- Ulcerativni kolitis10 študij
- Rak prostate10 študij
Vir: ClinicalTrials.gov, podatki pridobljeni 7. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.